SCHEMBL20964674

SCHEMBL20964674

Cc1cccc(N2CCN(C(=O)c3cccnc3SCc3cc(C)on3)CC2)c1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.51
TDP1 Q9NUW8 2/20 0.51
MAPT P10636 2/20 0.51
HTT P42858 2/20 0.51
TSHR P16473 4/20 0.44
ALDH1A1 P00352 3/20 0.44
LMNA P02545 3/20 0.44
SLC6A9 P48067 1/20 0.43
SLC6A5 Q9Y345 1/20 0.43
KDM4E B2RXH2 3/20 0.42
KMT2A Q03164 1/20 0.41
RECQL P46063 1/20 0.41
NPC1 O15118 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HPGD P15428 1/20 0.40
RAB9A P51151 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20964538 0.92 SMN1; SMN2 (0.51) SMN1; SMN2TDP1MAPTHTTTSHR
SCHEMBL20965325 0.92 MAPT (0.54) SMN1; SMN2TDP1MAPTHTTTSHR
SCHEMBL20965408 0.89 L3MBTL1 (0.55) SMN1; SMN2TDP1MAPTHTTTSHR
SCHEMBL20965301 0.88 PKM (0.53) SMN1; SMN2TDP1MAPTHTTTSHR
SCHEMBL20964660 0.86 SMN1; SMN2 (0.63) SMN1; SMN2TDP1MAPTHTTTSHR
SCHEMBL20964635 0.85 ALDH1A1 (0.63) SMN1; SMN2TDP1MAPTHTTTSHR
SCHEMBL20964624 0.84 GAA (0.47) SMN1; SMN2TDP1MAPTHTTTSHR
SCHEMBL20965430 0.83 MAPT (0.51) SMN1; SMN2TDP1MAPTHTTTSHR
SCHEMBL20964663 0.82 ALDH1A1 (0.47) SMN1; SMN2TDP1MAPTHTTTSHR
SCHEMBL20964566 0.81 ALDH1A1 (0.48) SMN1; SMN2TDP1MAPTHTTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2020-12-01 US disclosed
US-20190127361-A1 Therapeutic Compounds RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127361-A1 Therapeutic Compounds SDHA, SLC10A1, SERPINC1 SMN1; SMN2 263/4885TDP1 3109/4885MAPT 1626/4885
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents SERPINC1, F12, RPL35 SMN1; SMN2 2477/4885TDP1 1435/4885MAPT 4673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.